HURA TuHURA Biosciences, Inc./NV
company
SEC Filings & Insider Trading Activity 2026

CIK: 1498382
Health Care
Pharmaceutical Preparations 68 filings
Russell 2000

Latest TuHURA Biosciences, Inc./NV (HURA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 31, 2026, a 10-Q quarterly report filed on November 14, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for TuHURA Biosciences, Inc./NV (HURA) (SEC CIK 1498382), with AI-powered section-by-section summaries updated daily.

10-Q: 45
10-K: 15
8-K: 8

Latest 2026 SEC Filing Dates

10-K Annual Report
Mar 31, 2026
10-Q Quarterly Report
Nov 14, 2025
8-K Current Report
Apr 30, 2026

AI 10-Q Quarterly Report Analysis
Latest 10-Q (2025-09-30)

Risk Factors

  • New risk added: clinical hold lifted by FDA for Phase 3 trial of IFx-2.0 triggered milestone-based private placement funding of $12.6M in June 2025
  • Material update: Kineta Merger closed June 30, 2025, adding TBS-2025 asset and changing product pipeline and operational scope significantly
Read full Q3 2025 10-Q analysis →

Annual Reports Archive
10-K

AI-powered analysis of TuHURA Biosciences, Inc./NV (HURA) 10-K annual reports filed with SEC EDGAR.

Quarterly Reports Archive
10-Q

AI-powered analysis of TuHURA Biosciences, Inc./NV (HURA) 10-Q quarterly reports filed with SEC EDGAR.

Financial Summary
XBRL

FY2021FY2022FY2023FY2024FY2025
Profitability
Revenue$0$0$0
Net Income-$38.3M-$22.7M-$29.3M-$21.7M-$30.1M
Balance Sheet
Total Assets$13.5M$15.9M$4.4M$20.0M$27.4M
Equity$10.6M$12.3M-$1.6M$14.6M$20.9M
ROE-362.0%-184.2%1880.8%-148.6%-143.6%

Source: XBRL financial data from TuHURA Biosciences, Inc./NV (HURA) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Apr 30, 2026
8-K
Apr 22, 2026
8-K
Apr 8, 2026
8-K
Apr 1, 2026
10-K
Mar 31, 2026Dec 31, 2025
8-K
Jan 30, 2026
8-K
Dec 10, 2025
8-K
Dec 5, 2025
8-K
Nov 25, 2025
10-Q
Nov 14, 2025Sep 30, 2025Analysis
10-Q
Aug 14, 2025Jun 30, 2025
10-Q
May 15, 2025Mar 31, 2025
10-K
Mar 31, 2025Dec 31, 2024Analysis
10-Q
Nov 14, 2024Sep 30, 2024
10-K
Oct 7, 2024Jun 30, 2024Analysis
10-Q
May 14, 2024Mar 31, 2024
10-Q
Feb 14, 2024Dec 31, 2023
10-Q
Nov 13, 2023Sep 30, 2023
10-K
Sep 18, 2023Jun 30, 2023
10-Q
May 11, 2023Mar 31, 2023
10-Q
Feb 14, 2023Dec 31, 2022
10-Q
Nov 9, 2022Sep 30, 2022
10-K
Sep 27, 2022Jun 30, 2022
10-Q
May 13, 2022Mar 31, 2022
10-Q
Feb 11, 2022Dec 31, 2021

Frequently Asked Questions

What are the latest HURA SEC filings in 2026?

TuHURA Biosciences, Inc./NV (HURA) has filed a 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 14, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did HURA file its most recent 10-K annual report?

TuHURA Biosciences, Inc./NV (HURA) filed its most recent 10-K annual report on March 31, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view HURA 10-Q quarterly reports?

TuHURA Biosciences, Inc./NV (HURA)'s most recent 10-Q quarterly report was filed on November 14, 2025. SignalX displays every HURA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has HURA filed recently?

TuHURA Biosciences, Inc./NV (HURA)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find HURA insider trading activity (Form 4)?

SignalX aggregates every HURA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does HURA file with the SEC?

TuHURA Biosciences, Inc./NV (HURA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HURA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for TuHURA Biosciences, Inc./NV (HURA).

What is HURA's SEC CIK number?

TuHURA Biosciences, Inc./NV (HURA)'s SEC CIK (Central Index Key) number is 1498382. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1498382 to look up all HURA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find HURA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from TuHURA Biosciences, Inc./NV (HURA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of TuHURA Biosciences, Inc./NV SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 68+ filings.